Drug Safety and Effectiveness Network (DSEN): SEARCH-PREVENT (2018)
Well-being, Health and Biomedical Discovery
Deadlines
Academic Unit: Inquire with Unit
Memorial Deadline: Thursday 18th, January 2018
External Deadline: Tuesday 23rd, January 2018
Description
The purpose of this directed funding opportunity is to provide funding to the Drug Safety and Effectiveness Network (DSEN) Active Surveillance and Evaluation of Adverse Reactions in Canadian Healthcare Team (SEARCH) and the Pharmacogenomics of Adverse Events National Team (PREVENT). These teams, which will merge, are a major component of DSEN’s core capacity of linked research excellence.
DSEN was established to increase the evidence on drug safety and effectiveness available to public drug plan managers, regulators, policy-makers, health technology assessors and other end-users to support their decision-making and to increase capacity within Canada to undertake high-quality post-market drug safety and effectiveness research in this area. DSEN helps to reduce duplication of research efforts and facilitate collaboration of researchers across jurisdictions.
DSEN is currently comprised of the following research teams across Canada:
- Canadian Network for Observational Drug Effect Studies (CNODES)
- Canadian Network for Advanced Interdisciplinary Methods for Comparative Effectiveness Research (CAN-AIM)
- Pharmacogenomics of Adverse Events National Team (PREVENT)
- DSEN Active Surveillance and Evaluation of Adverse Drug Reactions in Canadian Healthcare Team (SEARCH)
- Methods and Applications Group for Indirect Comparisons (MAGIC)
These established research teams answer queries submitted by DSEN stakeholders. A DSEN query is a potential research topic identified as a gap in evidence on the safety and effectiveness of drugs on the Canadian market.
For additional details, visit CIHR’s website.